Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis

array:23 ["pii" => "S2173574324000108" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.01.003" "estado" => "S300" "fechaPublicacion" => "2024-02-01" "aid" => "1727" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2024;20:108-12" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S2173574324000212" "issn" => "21735743" "doi" => "10.1016/j.reumae.2023.07.006" "estado" => "S300" "fechaPublicacion" => "2024-02-01" "aid" => "1709" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2024;20:113" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Comments about treatment of glucocorticoid-induced osteoporosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "113" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Comentarios sobre el tratamiento de la osteoporosis por corticoides" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Osvaldo Daniel Messina" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Osvaldo Daniel" "apellidos" => "Messina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X23001778" "doi" => "10.1016/j.reuma.2023.07.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23001778?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000212?idApp=UINPBA00004M" "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000212/v1_202402220812/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S217357432400008X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.01.002" "estado" => "S300" "fechaPublicacion" => "2024-02-01" "aid" => "1711" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2024;20:104-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Case Report" "titulo" => "Pleural tuberculosis and endocarditis as complications of multifactorial origin in granulomatosis with polyangiitis: Clinical case report" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "104" "paginaFinal" => "107" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tuberculosis pleural y endocarditis como complicaciones de origen multifactorial en granulomatosis con poliangítis. Reporte de caso clinico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 575 "Ancho" => 1340 "Tamanyo" => 68180 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "(A) The CT scan showed ethmoidal sinusitis, bilateral maxillary and acute right sphenoid, septal deviation towards the left and frontal sinus hypoplasia. (B) Severe left pleural effusion, pneumothorax under tension but no evidence of nodular lesions." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús Anguamea-Maldonado, Eduardo Sanchez-Zazueta, Rene Vidal-Morales" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "Anguamea-Maldonado" ] 1 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Sanchez-Zazueta" ] 2 => array:2 [ "nombre" => "Rene" "apellidos" => "Vidal-Morales" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X23001894" "doi" => "10.1016/j.reuma.2023.08.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23001894?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432400008X?idApp=UINPBA00004M" "url" => "/21735743/0000002000000002/v1_202402220812/S217357432400008X/v1_202402220812/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Brief report" "titulo" => "Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "108" "paginaFinal" => "112" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ines Perez-Sancristobal, Paula Alvarez-Hernandez, Cristina Lajas-Petisco, Benjamin Fernandez-Gutierrez" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Ines" "apellidos" => "Perez-Sancristobal" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Paula" "apellidos" => "Alvarez-Hernandez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Cristina" "apellidos" => "Lajas-Petisco" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 3 => array:4 [ "nombre" => "Benjamin" "apellidos" => "Fernandez-Gutierrez" "email" => array:1 [ 0 => "benjamin.fernandez@salud.madrid.org" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "UGC Reumatologia, Hospital Clinico San Carlos, IdISSC, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universidad Complutense de Madrid. Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efecto del tratamiento combinado con prednisona y metotrexato versus prednisona sola sobre los parámetros de laboratorio en arteritis de células gigantes" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1592 "Ancho" => 1671 "Tamanyo" => 115163 ] ] "descripcion" => array:1 [ "en" => "Relationship between ESR and prednisone dose in each group. The gray line and gray rhombs indicate the mean ESR and median prednisone dose respectively in every time point for the patients treated with methotrexate and prednisone. The black line and black rectangles indicate the mean ESR and median prednisone dose in every time point for patients treated with prednisone alone. Arrows indicate the time at which relapses occurred in both groups. As you can see, relapses were more frequent in the first year of treatment in both groups and were accompanied by a significant rise in the mean ESR value." ] ] ] "textoCompleto" => "IntroductionGiant cell (temporal) arteritis (GCA) is a systemic vasculitis primarily targeting large and medium-sized arteries in people over the age of 50 years. It is characterized by transmural inflammation of the arteries that induces luminal occlusion through intimal hyperplasia. Clinical symptoms are developed by end-organ ischemia and, in almost all patients with GCA, a syndrome of systemic inflammation. GCA is characterized by a vigorous acute-phase response that includes increased levels of C-reactive protein (PCR) and, particularly, a very high erythrocyte sedimentation rate (ESR).Morbidity from GCA itself is substantial including vision loss, aortic aneurysms, aortic branch vessel stenoses, polymyalgia rheumatica (PMR), constitutional symptoms and stroke. Treatment with corticosteroids (CS) is mandatory,<a class="elsevierStyleCrossRef" href="#bib0175">1</a> initial dosage must be high (40–60mg/d) with subsequent tapering to a lower maintenance dose that is given for an average of two years. Following initial improvement, up to 60% of patients experience disease relapse during CS tapering requiring reintroduction or dose escalation of CS.<a class="elsevierStyleCrossRefs" href="#bib0180">2,3</a> This long-term CS therapy leads to CS-related adverse events in up 80% of patients being a major problem in the management of GCA in already frail patients.<a class="elsevierStyleCrossRef" href="#bib0190">4</a>Current data reflect that standard CS regimens only partially suppress vascular inflammation and that ongoing subclinical disease activity may expose GCA patients to the risk of progressive vascular disease and chronic systemic complications.<a class="elsevierStyleCrossRef" href="#bib0195">5</a> Indeed, it has not been demonstrated that corticosteroid treatment induces changes in the course of the disease. This hypothesis is supported by the absence of revascularization of affected vessels, a higher incidence of aneurysms in previously GCA patients, the findings of positive artery biopsies after a successful course of treatment, and the fact that percentage of asymptomatic GCA patients present sustained ESR or CRP elevations after treatment.In a previous study we have shown that methotrexate plus CS is a safe alternative to CS therapy alone in patients with GCA and is more effective in controlling disease than standard CS therapy.<a class="elsevierStyleCrossRef" href="#bib0200">6</a> Methotrexate plus CS was also more efficient than CS alone in maintaining disease remission supporting the notion that methotrexate may exert not only a role as steroid-sparing agent but also a role as disease-modifying agent in GCA.In this work, we study the effect of combined treatment with prednisone and MTX versus prednisone alone over laboratory parameters, particularly ESR as a marker of inflammation, in GCA.Patients and methodsPatientsSelection and randomization, follow-up, treatment protocol, assessments of disease activity and outcome measures are the same as the previously mentioned study.<a class="elsevierStyleCrossRef" href="#bib0200">6</a> Briefly, forty-two consecutive patients, newly diagnosed as having active GCA biopsy proven were included in the study and randomizing assigned to receive prednisone plus methotrexate or prednisone plus placebo.A single weekly dose of four tablets of either oral methotrexate (total 10mg/week) or placebo was started upon diagnosis, maintained throughout the treatment period, and finally interrupted after 24 months of follow-up if clinical signs of disease activity were absent. All patients received 60mg/day of oral prednisone in three divided doses during the first week, and once daily during the second week. Then, prednisone dose was gradually tapered by 10mg per week until reaching 40mg/day at the end of the first month; by 5mg per week until reaching 20mg by the end of the second month; and by 2.5mg every two weeks until complete withdrawn.Relapses were defined as the recurrence of symptoms of GCA after definite, objective improvement followed by symptom reversal upon resumption of, or increases in, the prednisone dose.Visits and laboratory parametersBaseline and follow-up visits were scheduled weekly during the first month, monthly until completion of the first year of therapy, and quarterly during the second year of follow-up. In each scheduled visit routine blood tests were performed including erythrocyte sedimentation rate (ESR), red blood cells, platelets, white blood cells, serum chemistry studies and urinalysis. In presence of suspected relapse and other adverse events, additional analysis was obtained.Statistical analysisLaboratory parameters were compared between patients receiving methotrexate and those receiving placebo along the study period. In order to analyze differences in mean laboratory values over time, we calculated the area under the curve (AUC) and adjusted the results by treatment group, dose of prednisone and existence of a relapse. A two-sided P value of 0.05 was the criteria for statistical significance in all cases. Categorical variables are presented as frequency distribution and quantitative variables as means plus/minus standard deviation (SD) if they fit a normal distribution, and median plus/minus first and third quartile if distribution is non-normal. Differences between treatment groups were analyzed using the two-tailed Student's t test and the Mann–Whitney U test for normal and non-normal quantitative variables respectively, with their corresponding 95% confidence interval when appropriate. Statistical comparisons were made with Arcus Quickstat Biomedical 1.2 software.ResultsThere were no significant differences among groups in terms of baseline characteristics (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). All patients had an elevated ESR at baseline that normalized shortly after initiation of treatment.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Time-course analysis of ESR values demonstrated that mean values of ESR were higher in those patients treated with placebo than in patients treated with methotrexate and this difference was evident after the fifth week of treatment (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The mean ESR value followed a parallel course in both groups, but was lower in the group with MTX than in the group with placebo in 18 of 20 time points of follow-up. Median value of ESR was 33 [18–56] in patients with placebo and 26 [15–44] in patients with MTX (P=0.0002). The area under the curve was significantly lower in patients treated with MTX than in patients treated with placebo (19,598.4±8,117 vs. 28,461.7±12,326, respectively; mean difference 8,863, 95% CI 1.542–16.184; P<0.01). This result was independent of prednisone dose, relapse status, age and sex.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Time course of relapses along the study period and prednisone use in both groups of treatment is shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>. ESR was elevated in 90% of relapses, median value 59mm/h, range 22–127 and no differences were observed in both groups. There was a peak of ESR between the third and fourth month that coincided with most relapses in both groups and with prednisone dose below 20mg/day. Differences in ESR appeared few weeks after treatment initiation and were maintained all along the treatment course even after one year of therapy when the median dose of prednisone was below 10mg in all patients.<elsevierMultimedia ident="fig0010"></elsevierMultimedia>The course of other laboratory parameters paralleled those observed for ESR but without statistical significance, with a trend to more normal parameters in patients treated with MTX, i.e., lower incidence of anemia, leucocytosis and thrombocytosis.DiscussionWe presented the analysis of the laboratory parameters in a group of patients with GCA treated with an identical schedule of prednisone plus methotrexate or placebo along a two-year study period. These patients were participants in a randomized, double-blind, placebo-controlled study that showed that combined treatment with prednisone and methotrexate reduced the proportions of patients suffering relapses and the mean cumulative dose of prednisone suggesting that methotrexate in association with CS are more effective in disease control than standard CS therapy. In this report, we go further suggesting that methotrexate may act as an anti-inflammatory modulator, and probably a disease-modifying factor, for GCA due to the observed decrease in acute-phase reactants.The differences appeared few weeks after treatment initiation and were maintained all along the treatment course even after one year of therapy when the mean dose of prednisone was below 10mg in all patients. Although not statistically significant, the course of other laboratory parameters paralleled those of ESR, with a better trend in patients treated with MTX. Due to the year of the original protocol design, 1992, neither CRP nor IL-6 or other pro-inflammatory cytokine levels were routinely considered, what would have been useful at the light of these results. However, differences observed point toward MTX not merely as a steroid-sparing agent but an anti-inflammatory modulator, and probably a disease-modifying factor, for GCA.The anti-inflammatory modulator concept is not new for rheumatologists but is a challenging new hypothesis for GCA.<a class="elsevierStyleCrossRef" href="#bib0205">7</a> None will now discuss that CS alone is not a proper treatment for chronic inflammatory diseases such as rheumatoid arthritis (RA). In fact, the concept of modification of inflammation versus symptoms modification has extended from RA to other several rheumatic and non-rheumatic diseases. Trials with MTX in GCA and polymyalgia rheumatica have been more that anecdotical in the literature.<a class="elsevierStyleCrossRefs" href="#bib0210">8–13</a>Although clinical results of other studies with MTX have been conflicting with ours and difficult to interpret,<a class="elsevierStyleCrossRefs" href="#bib0240">14–19,1</a> ESR showed also a trend favoring MTX in previous studies.<a class="elsevierStyleCrossRefs" href="#bib0270">20,21</a> Anti-TNF-α have also been studied and used in patients with GCA<a class="elsevierStyleCrossRefs" href="#bib0280">22–24</a> and failed to show efficacy in GCA, thus, anti-TNF therapies have not shown benefit in GCA.Other DMDs have been studied such as azathioprine<a class="elsevierStyleCrossRef" href="#bib0295">25</a> and leflunomide.<a class="elsevierStyleCrossRefs" href="#bib0300">26,27</a>Activated T cells have also been implicated in the pathogenesis of GCA, hence, abatacept (ABA) has been studied in a multicentre, randomized study<a class="elsevierStyleCrossRef" href="#bib0310">28</a> with promising results.IL-12 and IL-23 in the Th1 and Th17 responses are also recognized actors in the pathogenesis of GCA, therefore, ustekinumab, was studied in an open-label study of 14 patients with CGA.<a class="elsevierStyleCrossRef" href="#bib0315">29</a>The new prospects for GCA as well as polymyalgia rheumatica (PMR) include fairly evidence for a role of IL-6 in both GCA and PMR. Interleukin-6 includes acute-phase response and has a central role in the pathogenesis of GCA.<a class="elsevierStyleCrossRefs" href="#bib0320">30–32</a> The tocilizumab has been reported to be effective in several published randomized clinical trials.<a class="elsevierStyleCrossRefs" href="#bib0335">33,34</a>Although there is evidence in favor of treatment with other immunosuppressive drugs, in this article, we want to point out/emphasize the role of methotrexate as an anti-inflammatory modulator just decreasing VSG. Probably MTX could also act as a disease-modifying drug on its own taking into account the widespread evidence supporting/showing that MTX is safe and effective in the treatment of GCA and, in the background, it decreases acute-phase reactants.Conflict of interestThe authors declare that they have no conflict of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres2095022" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1785491" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2095023" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1785490" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Visits and laboratory parameters" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0030" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0035" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0040" "titulo" => "Conflict of interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-04-25" "fechaAceptado" => "2023-09-21" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1785491" "palabras" => array:2 [ 0 => "Giant cell arteritis" 1 => "Methotrexate" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1785490" "palabras" => array:2 [ 0 => "Arteritis de células gigantes" 1 => "Metotrexato" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "ObjectiveTo compare the effect of combined treatment with prednisone and methotrexate (MTX) versus prednisone alone over laboratory parameters in giant cell arteritis (GCA). Patients and methodsWe performed a double-blind, placebo-controlled, randomized clinical trial about usefulness of treatment with prednisone and MTX versus prednisone and placebo in GCA (Ann Intern Med 2001;134:106–114). As a part of follow-up of patients (n=42), we performed laboratory analysis in 20 time points during the two-year period of follow-up. To analyze differences, we calculated the area under the curve (AUC) for erythrocyte sedimentation rate (ESR), hemoglobin, and platelets, and compared the results in both groups adjusting by time of follow-up, existence of relapses and dose of prednisone. ResultsA total of 724 laboratory measurements were done. Median value of ESR was 33 [18–56] in patients with placebo and 26 [15–44] in patients with MTX (P=0.0002). No significant differences were observed in ESR during relapses. The mean ESR value followed a parallel course in both groups, but was lower in the group with MTX than in the group with placebo in 18 of 20 time points of follow-up. The AUC of ESR by time of follow-up was 28,461.7±12,326 in the group with placebo and 19,598.4±8,117 in the group with MTX (mean difference 8,863, 95% CI 1.542–16.184; P=0.019). The course of other laboratory parameters paralleled, without statistical significance, those observed for ESR. ConclusionsThese data, along with clinical data, suggest that MTX might play a role as a disease-modifying agent in the treatment of GCA." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "ObjetivoComparar el efecto del tratamiento combinado con prednisona y metotrexato (MTX) versus prednisona sola sobre parámetros de laboratorio en arteritis de células gigantes (ACG). Pacientes y métodosRealizamos un ensayo clínico aleatorizado, doble ciego, controlado con placebo sobre la utilidad del tratamiento con prednisona y MTX frente a prednisona y placebo en la ACG (Ann Intern Med. 2001;134:106-114). Como parte del seguimiento de los pacientes (n=42), realizamos análisis de laboratorio en 20 puntos temporales durante el período de seguimiento de 2 años. Para analizar diferencias calculamos el área bajo la curva (AUC) de VSG, hemoglobina y plaquetas, y comparamos los resultados en ambos grupos ajustando por tiempo de seguimiento, existencia de recaídas y dosis de prednisona. ResultadosSe realizaron un total de 724 mediciones de laboratorio. El valor medio de la VSG fue de 33 (18-56) en pacientes con placebo y de 26 (15-44) en pacientes con MTX (p=0,0002). No se observaron diferencias significativas en la VSG durante las recaídas. El valor medio de la VSG siguió un curso paralelo en ambos grupos, pero fue menor en el grupo con MTX que en el grupo con placebo en 18 de 20 puntos temporales de seguimiento. El AUC de la VSG por tiempo de seguimiento fue de 28.461,7±12.326 en el grupo con placebo y de 19.598,4±8.117 en el grupo con MTX (diferencia de medias 8.863; IC 95%: 1.542-16.184; p=0,019). La evolución de los demás parámetros de laboratorio fue paralela, sin significación estadística, a la observada para la VSG. ConclusionesEstos datos, junto con los datos clínicos, sugieren que el MTX podría desempeñar un papel como agente modificador de la enfermedad en el tratamiento de la ACG." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Supported by grants from FISPI 93/0739." ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1351 "Ancho" => 1675 "Tamanyo" => 118686 ] ] "descripcion" => array:1 [ "en" => "Time course of ESR in each group. The gray line indicates the mean ESR in every time point for the patients treated with methotrexate and prednisone and the black line the same value for patients treated with prednisone alone. Differences are apparent after the first month of treatment, and from then on, the mean ESR value was higher in the group treated with prednisone alone." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1592 "Ancho" => 1671 "Tamanyo" => 115163 ] ] "descripcion" => array:1 [ "en" => "Relationship between ESR and prednisone dose in each group. The gray line and gray rhombs indicate the mean ESR and median prednisone dose respectively in every time point for the patients treated with methotrexate and prednisone. The black line and black rectangles indicate the mean ESR and median prednisone dose in every time point for patients treated with prednisone alone. Arrows indicate the time at which relapses occurred in both groups. As you can see, relapses were more frequent in the first year of treatment in both groups and were accompanied by a significant rise in the mean ESR value." ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Characteristic \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Methotrexate group \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Placebo group \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">n=21 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">n=21 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age, y \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">78±8.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">77.6±7.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Women, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (66.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (71.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Body weight, kg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60.2±11.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.1±11.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Weeks before diagnosis, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.3±12.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.9±8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical features, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Polymyalgia rheumatica \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (57.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (52.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Abnormal temporal artery \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (76.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (71.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 (95.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Jaw claudication \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (57.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (80.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unilateral blindness<a class="elsevierStyleCrossRef" href="#tblfn0010">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (23.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bilateral blindness<a class="elsevierStyleCrossRef" href="#tblfn0015">‡</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (9.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (14.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Amaurosis fugax \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (4.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Laboratory values</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hemoglobin level, g/L \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">117±15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">112±15 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Platelet count, ×109cells/L \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">371±141 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">358±115 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Leukocyte count, ×109cells/L \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9.5±3.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.7±63.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erythrocyte sedimentation rate, mm/h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">91±24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100±26 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Previous concomitant disease, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arterial hypertension \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (33.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (47.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diabetes mellitus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (9.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (14.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cataracts \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (33.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (14.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Glaucoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (9.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tuberculosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (9.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cerebrovascular disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (4.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (4.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3466982.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "Values with the plus/minus sign are the mean±SD. P>0.10 for all paired comparisons between groups. No differences were observed between groups in either completion of follow-up or completion of treatment analysis." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "†" "nota" => "Includes complete (one patient) and partial (eight patients) unilateral blindness." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "‡" "nota" => "Includes complete (two patients) and partial (three patients) bilateral blindness. Ann Intern Med 2001;134:106–114." ] ] ] "descripcion" => array:1 [ "en" => "Baseline characteristics of the study patients.<a class="elsevierStyleCrossRef" href="#tblfn0005">*</a>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:34 [ 0 => array:3 [ "identificador" => "bib0175" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.Á. González-Gay" 1 => "T. Pina" 2 => "D. Prieto-Peña" 3 => "M. Calderon-Goercke" 4 => "O. Gualillo" 5 => "S. Castañeda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bcp.2019.04.027" "Revista" => array:6 [ "tituloSerie" => "Biochem Pharmacol" "fecha" => "2019" "volumen" => "165" "paginaInicial" => "230" "paginaFinal" => "239" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31034796" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0180" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic vasculitis in adults in northwestern Spain, 1988–1997. Clinical and epidemiologic aspects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.A. González-Gay" 1 => "C. García-Porrúa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/00005792-199909000-00002" "Revista" => array:6 [ "tituloSerie" => "Medicine" "fecha" => "1999" "volumen" => "78" "paginaInicial" => "292" "paginaFinal" => "308" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10499071" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0185" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow-up study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Salvarani" 1 => "F. Cantini" 2 => "L. Niccoli" 3 => "P. Macchioni" 4 => "D. Consonni" 5 => "G. Bajocchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20901" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "53" "paginaInicial" => "33" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15696567" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0190" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.S. Broder" 1 => "K. Sarsour" 2 => "E. Chang" 3 => "N. Collinson" 4 => "K. Tuckwell" 5 => "P. Napalkov" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2016.05.009" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2016" "volumen" => "46" "paginaInicial" => "246" "paginaFinal" => "252" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27378247" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0195" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Giant cell arteritis: a systemic vascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Tatò" 1 => "U. Hoffmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1358863x07085499" "Revista" => array:6 [ "tituloSerie" => "Vasc Med" "fecha" => "2008" "volumen" => "13" "paginaInicial" => "127" "paginaFinal" => "140" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18593802" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0200" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.A. Jover" 1 => "C. Hernández-García" 2 => "I.C. Morado" 3 => "E. Vargas" 4 => "A. Bañares" 5 => "B. Fernàndez-Gutiérrez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-134-2-200101160-00010" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2001" "volumen" => "134" "paginaInicial" => "106" "paginaFinal" => "114" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11177313" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0205" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate in giant cell arteritis deserves a second chance – a high-dose methotrexate trial is needed" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Brouwer" 1 => "K.S.M. van der Geest" 2 => "M. Sandovici" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.181306" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2019" "volumen" => "46" "paginaInicial" => "453" "paginaFinal" => "454" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31043498" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0210" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate for giant-cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G. Stollerman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Hosp Pract" "fecha" => "2023" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0215" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate for treating polymyalgia rheumatica: a meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G.G. Song" 1 => "Y.H. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5414/CP203901" "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pharmacol Ther" "fecha" => "2021" "volumen" => "59" "paginaInicial" => "366" "paginaFinal" => "371" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33480843" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0220" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "NCT00004686. Phase II randomized study of glucocorticoids with or without methotrexate for treatment of giant cell arteritis. <a target="_blank" href="https://clinicaltrials.gov/show/NCT00004686">https://clinicaltrials.gov/show/NCT00004686</a> [Internet]. Available from: <a target="_blank" href="https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01508295/full">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01508295/full</a> [cited 16.04.23]." ] ] ] 10 => array:3 [ "identificador" => "bib0225" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.J. Van Der Veen" 1 => "H.J. Dinant" 2 => "C. Van Booma-Frankfort" 3 => "G.A. Van Albada-Kuipers" 4 => "J.W.J. Bijlsma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.55.4.218" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "1996" "volumen" => "55" "paginaInicial" => "218" "paginaFinal" => "223" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8733437" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0230" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "CTRI/2021/07/035307. To understand the immunogenicity of Covisheild vaccine in patients with rheumatological disease by discontinuing methotrexate temporarily after taking second dose of vaccine. <a target="_blank" href="https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/07/035307">https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/07/035307</a> [Internet]. Available from: <a target="_blank" href="https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02328327/full">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02328327/full</a> [cited 16.04.23]." ] ] ] 12 => array:3 [ "identificador" => "bib0235" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D.E. Marsman" 1 => "T.E. Bolhuis" 2 => "N. den Broeder" 3 => "A.A. den Broeder" 4 => "A. van der Maas" ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1186/s13063-022-06263-3" "Revista" => array:5 [ "tituloSerie" => "Trials" "fecha" => "2022" "volumen" => "23" "paginaInicial" => "318" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35428320" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1186/s13063-022-06263-3" "WWW" => array:1 [ "link" => "https://doi.org/10.1186/s13063-022-06263-3" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0240" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FRI0216 steroid sparing effect lower incidence of disease relapse and diabetes in giant cell arteritis treated with immunosuppressors ab initio or very early: a multicenter retrospective case–control study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Quartuccio" 1 => "M. Isola" 2 => "D. Bruno" 3 => "E. Treppo" 4 => "L. Gigante" 5 => "F. Angelotti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2020" "volumen" => "79" "numero" => "Suppl. 1" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0245" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.L. Gérard" 1 => "N. Simon-Tillaux" 2 => "Y. Yordanov" 3 => "P. Cacoub" 4 => "F. Tubach" 5 => "D. Saadoun" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2021.03.040" "Revista" => array:7 [ "tituloSerie" => "Eur J Intern Med" "fecha" => "2021" "volumen" => "88" "paginaInicial" => "96" "paginaFinal" => "103" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33879385" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673619312796" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0250" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indirect comparison of glucocorticoid-sparing agents for remission maintenance in giant cell arteritis: a network meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Mainbourg" 1 => "A. Tabary" 2 => "M. Cucherat" 3 => "F. Gueyffier" 4 => "H. Lobbes" 5 => "M. Aussedat" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.mayocp.2022.03.010" "Revista" => array:7 [ "tituloSerie" => "Mayo Clin Proc" "fecha" => "2022" "volumen" => "97" "paginaInicial" => "1824" "paginaFinal" => "1835" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35995627" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1473309921004588" "estado" => "S300" "issn" => "14733099" ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0255" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparing treatment options for large vessel vasculitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Macaluso" 1 => "C. Marvisi" 2 => "P. Castrignanò" 3 => "N. Pipitone" 4 => "C. Salvarani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/1744666X.2022.2092098" "Revista" => array:7 [ "tituloSerie" => "Expert Rev Clin Immunol" "fecha" => "2022" "volumen" => "18" "paginaInicial" => "793" "paginaFinal" => "805" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35714219" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1473309921004539" "estado" => "S300" "issn" => "14733099" ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0260" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatments for giant cell arteritis: meta-analysis and assessment of estimates reliability using the fragility index" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Berti" 1 => "D. Cornec" 2 => "J.R. Medina Inojosa" 3 => "E.L. Matteson" 4 => "M.H. Murad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2017.12.009" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2018" "volumen" => "48" "paginaInicial" => "77" "paginaFinal" => "82" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29496228" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0265" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updates in the diagnosis and management of giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Uppal" 1 => "M. Hadi" 2 => "S. Chhaya" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11910-019-0982-3" "Revista" => array:5 [ "tituloSerie" => "Curr Neurol Neurosci Rep" "fecha" => "2019" "volumen" => "19" "paginaInicial" => "68" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31396718" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0270" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G.S. Hoffman" 1 => "R.Y. Leavitt" 2 => "G.S. Kerr" 3 => "M. Rottem" 4 => "M.C. Sneller" 5 => "A.S. Fauci" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1994" "volumen" => "37" "paginaInicial" => "578" "paginaFinal" => "582" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0275" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.S. Hoffman" 1 => "M.C. Cid" 2 => "D.B. Hellmann" 3 => "L. Guillevin" 4 => "J.H. Stone" 5 => "J. Schousboe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.10262" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2002" "volumen" => "46" "paginaInicial" => "1309" "paginaFinal" => "1318" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12115238" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0280" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Seror" 1 => "G. Baron" 2 => "E. Hachulla" 3 => "M. Debandt" 4 => "C. Larroche" 5 => "X. Puéchal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2013-203586" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2014" "volumen" => "73" "paginaInicial" => "2074" "paginaFinal" => "2081" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23897775" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0285" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V.M. Martínez-Taboada" 1 => "V. Rodríguez-Valverde" 2 => "L. Carreño" 3 => "J. López-Longo" 4 => "M. Figueroa" 5 => "J. Belzunegui" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.082115" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2008" "volumen" => "67" "paginaInicial" => "625" "paginaFinal" => "630" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18086726" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0290" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.S. Hoffman" 1 => "M.C. Cid" 2 => "K.E. Rendt-Zagar" 3 => "P.A. Merkel" 4 => "C.M. Weyand" 5 => "J.H. Stone" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-146-9-200705010-00004" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2007" "volumen" => "146" "paginaInicial" => "621" "paginaFinal" => "630" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17470830" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0295" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. De Silva" 1 => "B.L. Hazleman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.45.2.136" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "1986" "volumen" => "45" "paginaInicial" => "136" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3511861" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0300" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "T. Adizie" 1 => "D. Christidis" 2 => "C. Dharmapaliah" 3 => "F. Borg" 4 => "B. Dasgupta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1742-1241.2012.02981.x" "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pract" "fecha" => "2012" "volumen" => "66" "paginaInicial" => "906" "paginaFinal" => "909" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22897467" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0305" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.P. Diamantopoulos" 1 => "H. Hetland" 2 => "G. Myklebust" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Biomed Res Int" "fecha" => "2013" "volumen" => "2013" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0310" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.A. Langford" 1 => "D. Cuthbertson" 2 => "S.R. Ytterberg" 3 => "N. Khalidi" 4 => "P.A. Monach" 5 => "S. Carette" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40044" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2017" "volumen" => "69" "paginaInicial" => "837" "paginaFinal" => "845" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28133925" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0315" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab for the treatment of refractory giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Conway" 1 => "L. O’Neill" 2 => "E. O’Flynn" 3 => "P. Gallagher" 4 => "G.M. McCarthy" 5 => "C.C. Murphy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2016-209351" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2016" "volumen" => "75" "paginaInicial" => "1578" "paginaFinal" => "1579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27143653" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0320" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.M. Weyand" 1 => "K.C. Hicok" 2 => "G.G. Hunder" 3 => "J.J. Goronzy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-121-7-199410010-00003" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "1994" "volumen" => "121" "paginaInicial" => "484" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8067646" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0325" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.M. Weyand" 1 => "J.W. Fulbright" 2 => "G.G. Hunder" 3 => "J.M. Evans" 4 => "J.J. Goronzy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2000" "volumen" => "43" "paginaInicial" => "1041" "paginaFinal" => "1048" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10817557" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0330" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.M. Weyand" 1 => "B.R. Younge" 2 => "J.J. Goronzy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0b013e32833ee946" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Rheumatol" "fecha" => "2011" "volumen" => "23" "paginaInicial" => "43" "paginaFinal" => "49" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20827207" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0335" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trial of tocilizumab in giant-cell arteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.H. Stone" 1 => "K. Tuckwell" 2 => "S. Dimonaco" 3 => "M. Klearman" 4 => "M. Aringer" 5 => "D. Blockmans" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1613849" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "377" "paginaInicial" => "317" "paginaFinal" => "328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28745999" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0340" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.M. Villiger" 1 => "S. Adler" 2 => "S. Kuchen" 3 => "F. Wermelinger" 4 => "D. Dan" 5 => "V. Fiege" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(16)00560-2" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2016" "volumen" => "387" "paginaInicial" => "1921" "paginaFinal" => "1927" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26952547" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000108/v1_202402220812/en/main.assets" "Apartado" => array:4 [ "identificador" => "67860" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case reports" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000002000000002/v1_202402220812/S2173574324000108/v1_202402220812/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000108?idApp=UINPBA00004M"]

Statistics

Brief report

Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis

Efecto del tratamiento combinado con prednisona y metotrexato versus prednisona sola sobre los parámetros de laboratorio en arteritis de células gigantes

Ines Perez-Sancristobala, Paula Alvarez-Hernandeza, Cristina Lajas-Petiscoa,b, Benjamin Fernandez-Gutierreza,b,

Corresponding author

benjamin.fernandez@salud.madrid.org

Corresponding author.

a UGC Reumatologia, Hospital Clinico San Carlos, IdISSC, Madrid, Spain

b Universidad Complutense de Madrid. Spain

Read

262

Times
was read the article

114

Total PDF

148

Total HTML

Share statistics

 array:23 [
  "pii" => "S2173574324000108"
  "issn" => "21735743"
  "doi" => "10.1016/j.reumae.2024.01.003"
  "estado" => "S300"
  "fechaPublicacion" => "2024-02-01"
  "aid" => "1727"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
  "copyrightAnyo" => "2023"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Reumatol Clin. 2024;20:108-12"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2173574324000212"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2023.07.006"
    "estado" => "S300"
    "fechaPublicacion" => "2024-02-01"
    "aid" => "1709"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Reumatol Clin. 2024;20:113"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Comments about treatment of glucocorticoid-induced osteoporosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "113"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Comentarios sobre el tratamiento de la osteoporosis por corticoides"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Osvaldo Daniel Messina"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Osvaldo Daniel"
              "apellidos" => "Messina"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1699258X23001778"
        "doi" => "10.1016/j.reuma.2023.07.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23001778?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000212?idApp=UINPBA00004M"
    "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000212/v1_202402220812/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S217357432400008X"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2024.01.002"
    "estado" => "S300"
    "fechaPublicacion" => "2024-02-01"
    "aid" => "1711"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Reumatol Clin. 2024;20:104-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>"
      "titulo" => "Pleural tuberculosis and endocarditis as complications of multifactorial origin in granulomatosis with polyangiitis&#58; Clinical case report"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "104"
          "paginaFinal" => "107"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Tuberculosis pleural y endocarditis como complicaciones de origen multifactorial en granulomatosis con poliang&#237;tis&#46; Reporte de caso clinico"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 575
              "Ancho" => 1340
              "Tamanyo" => 68180
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; The CT scan showed ethmoidal sinusitis&#44; bilateral maxillary and acute right sphenoid&#44; septal deviation towards the left and frontal sinus hypoplasia&#46; &#40;B&#41; Severe left pleural effusion&#44; pneumothorax under tension but no evidence of nodular lesions&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jes&#250;s Anguamea-Maldonado, Eduardo Sanchez-Zazueta, Rene Vidal-Morales"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Jes&#250;s"
              "apellidos" => "Anguamea-Maldonado"
            ]
            1 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Sanchez-Zazueta"
            ]
            2 => array:2 [
              "nombre" => "Rene"
              "apellidos" => "Vidal-Morales"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1699258X23001894"
        "doi" => "10.1016/j.reuma.2023.08.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23001894?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432400008X?idApp=UINPBA00004M"
    "url" => "/21735743/0000002000000002/v1_202402220812/S217357432400008X/v1_202402220812/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>"
    "titulo" => "Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "108"
        "paginaFinal" => "112"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ines Perez-Sancristobal, Paula Alvarez-Hernandez, Cristina Lajas-Petisco, Benjamin Fernandez-Gutierrez"
        "autores" => array:4 [
          0 => array:3 [
            "nombre" => "Ines"
            "apellidos" => "Perez-Sancristobal"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Paula"
            "apellidos" => "Alvarez-Hernandez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Lajas-Petisco"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:4 [
            "nombre" => "Benjamin"
            "apellidos" => "Fernandez-Gutierrez"
            "email" => array:1 [
              0 => "benjamin.fernandez@salud.madrid.org"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "UGC Reumatologia&#44; Hospital Clinico San Carlos&#44; IdISSC&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Universidad Complutense de Madrid&#46; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Efecto del tratamiento combinado con prednisona y metotrexato versus prednisona sola sobre los par&#225;metros de laboratorio en arteritis de c&#233;lulas gigantes"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1592
            "Ancho" => 1671
            "Tamanyo" => 115163
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Relationship between ESR and prednisone dose in each group&#46; The gray line and gray rhombs indicate the mean ESR and median prednisone dose respectively in every time point for the patients treated with methotrexate and prednisone&#46; The black line and black rectangles indicate the mean ESR and median prednisone dose in every time point for patients treated with prednisone alone&#46; Arrows indicate the time at which relapses occurred in both groups&#46; As you can see&#44; relapses were more frequent in the first year of treatment in both groups and were accompanied by a significant rise in the mean ESR value&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Giant cell &#40;temporal&#41; arteritis &#40;GCA&#41; is a systemic vasculitis primarily targeting large and medium-sized arteries in people over the age of 50 years&#46; It is characterized by transmural inflammation of the arteries that induces luminal occlusion through intimal hyperplasia&#46; Clinical symptoms are developed by end-organ ischemia and&#44; in almost all patients with GCA&#44; a syndrome of systemic inflammation&#46; GCA is characterized by a vigorous acute-phase response that includes increased levels of C-reactive protein &#40;PCR&#41; and&#44; particularly&#44; a very high erythrocyte sedimentation rate &#40;ESR&#41;&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Morbidity from GCA itself is substantial including vision loss&#44; aortic aneurysms&#44; aortic branch vessel stenoses&#44; polymyalgia rheumatica &#40;PMR&#41;&#44; constitutional symptoms and stroke&#46; Treatment with corticosteroids &#40;CS&#41; is mandatory&#44;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">1</span></a> initial dosage must be high &#40;40&#8211;60<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41; with subsequent tapering to a lower maintenance dose that is given for an average of two years&#46; Following initial improvement&#44; up to 60&#37; of patients experience disease relapse during CS tapering requiring reintroduction or dose escalation of CS&#46;<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">2&#44;3</span></a> This long-term CS therapy leads to CS-related adverse events in up 80&#37; of patients being a major problem in the management of GCA in already frail patients&#46;<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Current data reflect that standard CS regimens only partially suppress vascular inflammation and that ongoing subclinical disease activity may expose GCA patients to the risk of progressive vascular disease and chronic systemic complications&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">5</span></a> Indeed&#44; it has not been demonstrated that corticosteroid treatment induces changes in the course of the disease&#46; This hypothesis is supported by the absence of revascularization of affected vessels&#44; a higher incidence of aneurysms in previously GCA patients&#44; the findings of positive artery biopsies after a successful course of treatment&#44; and the fact that percentage of asymptomatic GCA patients present sustained ESR or CRP elevations after treatment&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">In a previous study we have shown that methotrexate plus CS is a safe alternative to CS therapy alone in patients with GCA and is more effective in controlling disease than standard CS therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">6</span></a> Methotrexate plus CS was also more efficient than CS alone in maintaining disease remission supporting the notion that methotrexate may exert not only a role as steroid-sparing agent but also a role as disease-modifying agent in GCA&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">In this work&#44; we study the effect of combined treatment with prednisone and MTX versus prednisone alone over laboratory parameters&#44; particularly ESR as a marker of inflammation&#44; in GCA&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients</span><p id="par0030" class="elsevierStylePara elsevierViewall">Selection and randomization&#44; follow-up&#44; treatment protocol&#44; assessments of disease activity and outcome measures are the same as the previously mentioned study&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">6</span></a> Briefly&#44; forty-two consecutive patients&#44; newly diagnosed as having active GCA biopsy proven were included in the study and randomizing assigned to receive prednisone plus methotrexate or prednisone plus placebo&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">A single weekly dose of four tablets of either oral methotrexate &#40;total 10<span class="elsevierStyleHsp" style=""></span>mg&#47;week&#41; or placebo was started upon diagnosis&#44; maintained throughout the treatment period&#44; and finally interrupted after 24 months of follow-up if clinical signs of disease activity were absent&#46; All patients received 60<span class="elsevierStyleHsp" style=""></span>mg&#47;day of oral prednisone in three divided doses during the first week&#44; and once daily during the second week&#46; Then&#44; prednisone dose was gradually tapered by 10<span class="elsevierStyleHsp" style=""></span>mg per week until reaching 40<span class="elsevierStyleHsp" style=""></span>mg&#47;day at the end of the first month&#59; by 5<span class="elsevierStyleHsp" style=""></span>mg per week until reaching 20<span class="elsevierStyleHsp" style=""></span>mg by the end of the second month&#59; and by 2&#46;5<span class="elsevierStyleHsp" style=""></span>mg every two weeks until complete withdrawn&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Relapses were defined as the recurrence of symptoms of GCA after definite&#44; objective improvement followed by symptom reversal upon resumption of&#44; or increases in&#44; the prednisone dose&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Visits and laboratory parameters</span><p id="par0045" class="elsevierStylePara elsevierViewall">Baseline and follow-up visits were scheduled weekly during the first month&#44; monthly until completion of the first year of therapy&#44; and quarterly during the second year of follow-up&#46; In each scheduled visit routine blood tests were performed including erythrocyte sedimentation rate &#40;ESR&#41;&#44; red blood cells&#44; platelets&#44; white blood cells&#44; serum chemistry studies and urinalysis&#46; In presence of suspected relapse and other adverse events&#44; additional analysis was obtained&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0050" class="elsevierStylePara elsevierViewall">Laboratory parameters were compared between patients receiving methotrexate and those receiving placebo along the study period&#46; In order to analyze differences in mean laboratory values over time&#44; we calculated the area under the curve &#40;AUC&#41; and adjusted the results by treatment group&#44; dose of prednisone and existence of a relapse&#46; A two-sided <span class="elsevierStyleItalic">P</span> value of 0&#46;05 was the criteria for statistical significance in all cases&#46; Categorical variables are presented as frequency distribution and quantitative variables as means plus&#47;minus standard deviation &#40;SD&#41; if they fit a normal distribution&#44; and median plus&#47;minus first and third quartile if distribution is non-normal&#46; Differences between treatment groups were analyzed using the two-tailed Student&#39;s <span class="elsevierStyleItalic">t</span> test and the Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span> test for normal and non-normal quantitative variables respectively&#44; with their corresponding 95&#37; confidence interval when appropriate&#46; Statistical comparisons were made with Arcus Quickstat Biomedical 1&#46;2 software&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><p id="par0055" class="elsevierStylePara elsevierViewall">There were no significant differences among groups in terms of baseline characteristics &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; All patients had an elevated ESR at baseline that normalized shortly after initiation of treatment&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Time-course analysis of ESR values demonstrated that mean values of ESR were higher in those patients treated with placebo than in patients treated with methotrexate and this difference was evident after the fifth week of treatment &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; The mean ESR value followed a parallel course in both groups&#44; but was lower in the group with MTX than in the group with placebo in 18 of 20 time points of follow-up&#46; Median value of ESR was 33 &#91;18&#8211;56&#93; in patients with placebo and 26 &#91;15&#8211;44&#93; in patients with MTX &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;0002&#41;&#46; The area under the curve was significantly lower in patients treated with MTX than in patients treated with placebo &#40;19&#44;598&#46;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&#44;117 vs&#46; 28&#44;461&#46;7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;326&#44; respectively&#59; mean difference 8&#44;863&#44; 95&#37; CI 1&#46;542&#8211;16&#46;184&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;01&#41;&#46; This result was independent of prednisone dose&#44; relapse status&#44; age and sex&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">Time course of relapses along the study period and prednisone use in both groups of treatment is shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#46; ESR was elevated in 90&#37; of relapses&#44; median value 59<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#44; range 22&#8211;127 and no differences were observed in both groups&#46; There was a peak of ESR between the third and fourth month that coincided with most relapses in both groups and with prednisone dose below 20<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; Differences in ESR appeared few weeks after treatment initiation and were maintained all along the treatment course even after one year of therapy when the median dose of prednisone was below 10<span class="elsevierStyleHsp" style=""></span>mg in all patients&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">The course of other laboratory parameters paralleled those observed for ESR but without statistical significance&#44; with a trend to more normal parameters in patients treated with MTX&#44; i&#46;e&#46;&#44; lower incidence of anemia&#44; leucocytosis and thrombocytosis&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Discussion</span><p id="par0075" class="elsevierStylePara elsevierViewall">We presented the analysis of the laboratory parameters in a group of patients with GCA treated with an identical schedule of prednisone plus methotrexate or placebo along a two-year study period&#46; These patients were participants in a randomized&#44; double-blind&#44; placebo-controlled study that showed that combined treatment with prednisone and methotrexate reduced the proportions of patients suffering relapses and the mean cumulative dose of prednisone suggesting that methotrexate in association with CS are more effective in disease control than standard CS therapy&#46; In this report&#44; we go further suggesting that methotrexate may act as an anti-inflammatory modulator&#44; and probably a disease-modifying factor&#44; for GCA due to the observed decrease in acute-phase reactants&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">The differences appeared few weeks after treatment initiation and were maintained all along the treatment course even after one year of therapy when the mean dose of prednisone was below 10<span class="elsevierStyleHsp" style=""></span>mg in all patients&#46; Although not statistically significant&#44; the course of other laboratory parameters paralleled those of ESR&#44; with a better trend in patients treated with MTX&#46; Due to the year of the original protocol design&#44; 1992&#44; neither CRP nor IL-6 or other pro-inflammatory cytokine levels were routinely considered&#44; what would have been useful at the light of these results&#46; However&#44; differences observed point toward MTX not merely as a steroid-sparing agent but an anti-inflammatory modulator&#44; and probably a disease-modifying factor&#44; for GCA&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">The anti-inflammatory modulator concept is not new for rheumatologists but is a challenging new hypothesis for GCA&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">7</span></a> None will now discuss that CS alone is not a proper treatment for chronic inflammatory diseases such as rheumatoid arthritis &#40;RA&#41;&#46; In fact&#44; the concept of modification of inflammation versus symptoms modification has extended from RA to other several rheumatic and non-rheumatic diseases&#46; Trials with MTX in GCA and polymyalgia rheumatica have been more that anecdotical in the literature&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">8&#8211;13</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Although clinical results of other studies with MTX have been conflicting with ours and difficult to interpret&#44;<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">14&#8211;19&#44;1</span></a> ESR showed also a trend favoring MTX in previous studies&#46;<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">20&#44;21</span></a> Anti-TNF-&#945; have also been studied and used in patients with GCA<a class="elsevierStyleCrossRefs" href="#bib0280"><span class="elsevierStyleSup">22&#8211;24</span></a> and failed to show efficacy in GCA&#44; thus&#44; anti-TNF therapies have not shown benefit in GCA&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Other DMDs have been studied such as azathioprine<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">25</span></a> and leflunomide&#46;<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">26&#44;27</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Activated T cells have also been implicated in the pathogenesis of GCA&#44; hence&#44; abatacept &#40;ABA&#41; has been studied in a multicentre&#44; randomized study<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">28</span></a> with promising results&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">IL-12 and IL-23 in the Th1 and Th17 responses are also recognized actors in the pathogenesis of GCA&#44; therefore&#44; ustekinumab&#44; was studied in an open-label study of 14 patients with CGA&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">29</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">The new prospects for GCA as well as polymyalgia rheumatica &#40;PMR&#41; include fairly evidence for a role of IL-6 in both GCA and PMR&#46; Interleukin-6 includes acute-phase response and has a central role in the pathogenesis of GCA&#46;<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">30&#8211;32</span></a> The tocilizumab has been reported to be effective in several published randomized clinical trials&#46;<a class="elsevierStyleCrossRefs" href="#bib0335"><span class="elsevierStyleSup">33&#44;34</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Although there is evidence in favor of treatment with other immunosuppressive drugs&#44; in this article&#44; we want to point out&#47;emphasize the role of methotrexate as an anti-inflammatory modulator just decreasing VSG&#46; Probably MTX could also act as a disease-modifying drug on its own taking into account the widespread evidence supporting&#47;showing that MTX is safe and effective in the treatment of GCA and&#44; in the background&#44; it decreases acute-phase reactants&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflict of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:10 [
        0 => array:3 [
          "identificador" => "xres2095022"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Objective"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Patients and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1785491"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres2095023"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Objetivo"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Pacientes y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1785490"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Patients and methods"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Patients"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Visits and laboratory parameters"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        6 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Conflict of interest"
        ]
        9 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-04-25"
    "fechaAceptado" => "2023-09-21"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1785491"
          "palabras" => array:2 [
            0 => "Giant cell arteritis"
            1 => "Methotrexate"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1785490"
          "palabras" => array:2 [
            0 => "Arteritis de c&#233;lulas gigantes"
            1 => "Metotrexato"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To compare the effect of combined treatment with prednisone and methotrexate &#40;MTX&#41; versus prednisone alone over laboratory parameters in giant cell arteritis &#40;GCA&#41;&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We performed a double-blind&#44; placebo-controlled&#44; randomized clinical trial about usefulness of treatment with prednisone and MTX versus prednisone and placebo in GCA &#40;Ann Intern Med 2001&#59;134&#58;106&#8211;114&#41;&#46; As a part of follow-up of patients &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>42&#41;&#44; we performed laboratory analysis in 20 time points during the two-year period of follow-up&#46; To analyze differences&#44; we calculated the area under the curve &#40;AUC&#41; for erythrocyte sedimentation rate &#40;ESR&#41;&#44; hemoglobin&#44; and platelets&#44; and compared the results in both groups adjusting by time of follow-up&#44; existence of relapses and dose of prednisone&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A total of 724 laboratory measurements were done&#46; Median value of ESR was 33 &#91;18&#8211;56&#93; in patients with placebo and 26 &#91;15&#8211;44&#93; in patients with MTX &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;0002&#41;&#46; No significant differences were observed in ESR during relapses&#46; The mean ESR value followed a parallel course in both groups&#44; but was lower in the group with MTX than in the group with placebo in 18 of 20 time points of follow-up&#46; The AUC of ESR by time of follow-up was 28&#44;461&#46;7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;326 in the group with placebo and 19&#44;598&#46;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&#44;117 in the group with MTX &#40;mean difference 8&#44;863&#44; 95&#37; CI 1&#46;542&#8211;16&#46;184&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;019&#41;&#46; The course of other laboratory parameters paralleled&#44; without statistical significance&#44; those observed for ESR&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">These data&#44; along with clinical data&#44; suggest that MTX might play a role as a disease-modifying agent in the treatment of GCA&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Patients and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Comparar el efecto del tratamiento combinado con prednisona y metotrexato &#40;MTX&#41; versus prednisona sola sobre par&#225;metros de laboratorio en arteritis de c&#233;lulas gigantes &#40;ACG&#41;&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y m&#233;todos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Realizamos un ensayo cl&#237;nico aleatorizado&#44; doble ciego&#44; controlado con placebo sobre la utilidad del tratamiento con prednisona y MTX frente a prednisona y placebo en la ACG &#40;Ann Intern Med&#46; 2001&#59;134&#58;106-114&#41;&#46; Como parte del seguimiento de los pacientes &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>42&#41;&#44; realizamos an&#225;lisis de laboratorio en 20 puntos temporales durante el per&#237;odo de seguimiento de 2 a&#241;os&#46; Para analizar diferencias calculamos el &#225;rea bajo la curva &#40;AUC&#41; de VSG&#44; hemoglobina y plaquetas&#44; y comparamos los resultados en ambos grupos ajustando por tiempo de seguimiento&#44; existencia de reca&#237;das y dosis de prednisona&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se realizaron un total de 724 mediciones de laboratorio&#46; El valor medio de la VSG fue de 33 &#40;18-56&#41; en pacientes con placebo y de 26 &#40;15-44&#41; en pacientes con MTX &#40;p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;0002&#41;&#46; No se observaron diferencias significativas en la VSG durante las reca&#237;das&#46; El valor medio de la VSG sigui&#243; un curso paralelo en ambos grupos&#44; pero fue menor en el grupo con MTX que en el grupo con placebo en 18 de 20 puntos temporales de seguimiento&#46; El AUC de la VSG por tiempo de seguimiento fue de 28&#46;461&#44;7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#46;326 en el grupo con placebo y de 19&#46;598&#44;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&#46;117 en el grupo con MTX &#40;diferencia de medias 8&#46;863&#59; IC 95&#37;&#58; 1&#46;542-16&#46;184&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;019&#41;&#46; La evoluci&#243;n de los dem&#225;s par&#225;metros de laboratorio fue paralela&#44; sin significaci&#243;n estad&#237;stica&#44; a la observada para la VSG&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Estos datos&#44; junto con los datos cl&#237;nicos&#44; sugieren que el MTX podr&#237;a desempe&#241;ar un papel como agente modificador de la enfermedad en el tratamiento de la ACG&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Pacientes y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Supported by grants from <span class="elsevierStyleGrantSponsor" id="gs0005">FIS</span><span class="elsevierStyleGrantNumber" refid="gs0005">PI 93&#47;0739</span>&#46;</p>"
      ]
    ]
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1351
            "Ancho" => 1675
            "Tamanyo" => 118686
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Time course of ESR in each group&#46; The gray line indicates the mean ESR in every time point for the patients treated with methotrexate and prednisone and the black line the same value for patients treated with prednisone alone&#46; Differences are apparent after the first month of treatment&#44; and from then on&#44; the mean ESR value was higher in the group treated with prednisone alone&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1592
            "Ancho" => 1671
            "Tamanyo" => 115163
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Relationship between ESR and prednisone dose in each group&#46; The gray line and gray rhombs indicate the mean ESR and median prednisone dose respectively in every time point for the patients treated with methotrexate and prednisone&#46; The black line and black rectangles indicate the mean ESR and median prednisone dose in every time point for patients treated with prednisone alone&#46; Arrows indicate the time at which relapses occurred in both groups&#46; As you can see&#44; relapses were more frequent in the first year of treatment in both groups and were accompanied by a significant rise in the mean ESR value&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Characteristic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Methotrexate group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Placebo group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Age&#44; y</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">78<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>7&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Women&#44; n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;71&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Body weight&#44; kg</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60&#46;2<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>11&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">58&#46;1<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>11&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Weeks before diagnosis&#44; n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#46;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46;9<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Clinical features&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Polymyalgia rheumatica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;57&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;52&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Abnormal temporal artery&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;76&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;71&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Headache&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;95&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Jaw claudication&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;57&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;80&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Unilateral blindness<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;19&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;23&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bilateral blindness<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;9&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Amaurosis fugax&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;4&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Laboratory values</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hemoglobin level&#44; g&#47;L&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">117<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">112<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Platelet count&#44; &#215;10<span class="elsevierStyleSup">9</span><span class="elsevierStyleHsp" style=""></span>cells&#47;L&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">371<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>141&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">358<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>115&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leukocyte count&#44; &#215;10<span class="elsevierStyleSup">9</span><span class="elsevierStyleHsp" style=""></span>cells&#47;L&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#46;5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46;7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>63&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Erythrocyte sedimentation rate&#44; mm&#47;h&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">91<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Previous concomitant disease&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Arterial hypertension&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;47&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diabetes mellitus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;9&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cataracts&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Glaucoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;9&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tuberculosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;19&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;9&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cerebrovascular disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;4&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;4&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3466982.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Values with the plus&#47;minus sign are the mean<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>SD&#46; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>0&#46;10 for all paired comparisons between groups&#46; No differences were observed between groups in either completion of follow-up or completion of treatment analysis&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Includes complete &#40;one patient&#41; and partial &#40;eight patients&#41; unilateral blindness&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Includes complete &#40;two patients&#41; and partial &#40;three patients&#41; bilateral blindness&#46;</p> <p class="elsevierStyleNotepara" id="npar0020">Ann Intern Med 2001&#59;134&#58;106&#8211;114&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of the study patients&#46;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a></p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:34 [
            0 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46;&#193;&#46; Gonz&#225;lez-Gay"
                            1 => "T&#46; Pina"
                            2 => "D&#46; Prieto-Pe&#241;a"
                            3 => "M&#46; Calderon-Goercke"
                            4 => "O&#46; Gualillo"
                            5 => "S&#46; Casta&#241;eda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.bcp.2019.04.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "Biochem Pharmacol"
                        "fecha" => "2019"
                        "volumen" => "165"
                        "paginaInicial" => "230"
                        "paginaFinal" => "239"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31034796"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic vasculitis in adults in northwestern Spain&#44; 1988&#8211;1997&#46; Clinical and epidemiologic aspects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;A&#46; Gonz&#225;lez-Gay"
                            1 => "C&#46; Garc&#237;a-Porr&#250;a"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/00005792-199909000-00002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Medicine"
                        "fecha" => "1999"
                        "volumen" => "78"
                        "paginaInicial" => "292"
                        "paginaFinal" => "308"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10499071"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute-phase reactants and the risk of relapse&#47;recurrence in polymyalgia rheumatica&#58; a prospective follow-up study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Salvarani"
                            1 => "F&#46; Cantini"
                            2 => "L&#46; Niccoli"
                            3 => "P&#46; Macchioni"
                            4 => "D&#46; Consonni"
                            5 => "G&#46; Bajocchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.20901"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2005"
                        "volumen" => "53"
                        "paginaInicial" => "33"
                        "paginaFinal" => "38"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15696567"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Corticosteroid-related adverse events in patients with giant cell arteritis&#58; a claims-based analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;S&#46; Broder"
                            1 => "K&#46; Sarsour"
                            2 => "E&#46; Chang"
                            3 => "N&#46; Collinson"
                            4 => "K&#46; Tuckwell"
                            5 => "P&#46; Napalkov"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2016.05.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum"
                        "fecha" => "2016"
                        "volumen" => "46"
                        "paginaInicial" => "246"
                        "paginaFinal" => "252"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27378247"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Giant cell arteritis&#58; a systemic vascular disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Tat&#242;"
                            1 => "U&#46; Hoffmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1358863x07085499"
                      "Revista" => array:6 [
                        "tituloSerie" => "Vasc Med"
                        "fecha" => "2008"
                        "volumen" => "13"
                        "paginaInicial" => "127"
                        "paginaFinal" => "140"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18593802"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combined treatment of giant-cell arteritis with methotrexate and prednisone&#58; a randomized&#44; double-blind&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Jover"
                            1 => "C&#46; Hern&#225;ndez-Garc&#237;a"
                            2 => "I&#46;C&#46; Morado"
                            3 => "E&#46; Vargas"
                            4 => "A&#46; Ba&#241;ares"
                            5 => "B&#46; Fern&#224;ndez-Guti&#233;rrez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-134-2-200101160-00010"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2001"
                        "volumen" => "134"
                        "paginaInicial" => "106"
                        "paginaFinal" => "114"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11177313"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate in giant cell arteritis deserves a second chance &#8211; a high-dose methotrexate trial is needed"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46; Brouwer"
                            1 => "K&#46;S&#46;M&#46; van der Geest"
                            2 => "M&#46; Sandovici"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.181306"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2019"
                        "volumen" => "46"
                        "paginaInicial" => "453"
                        "paginaFinal" => "454"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31043498"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate for giant-cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46; Stollerman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Hosp Pract"
                        "fecha" => "2023"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate for treating polymyalgia rheumatica&#58; a meta-analysis of randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46;G&#46; Song"
                            1 => "Y&#46;H&#46; Lee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5414/CP203901"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Clin Pharmacol Ther"
                        "fecha" => "2021"
                        "volumen" => "59"
                        "paginaInicial" => "366"
                        "paginaFinal" => "371"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33480843"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "NCT00004686&#46; Phase II randomized study of glucocorticoids with or without methotrexate for treatment of giant cell arteritis&#46; <a target="_blank" href="https://clinicaltrials.gov/show/NCT00004686">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;show&#47;NCT00004686</a> &#91;Internet&#93;&#46; Available from&#58; <a target="_blank" href="https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01508295/full">https&#58;&#47;&#47;www&#46;cochranelibrary&#46;com&#47;central&#47;doi&#47;10&#46;1002&#47;central&#47;CN-01508295&#47;full</a> &#91;cited 16&#46;04&#46;23&#93;&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46;J&#46; Van Der Veen"
                            1 => "H&#46;J&#46; Dinant"
                            2 => "C&#46; Van Booma-Frankfort"
                            3 => "G&#46;A&#46; Van Albada-Kuipers"
                            4 => "J&#46;W&#46;J&#46; Bijlsma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.55.4.218"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "1996"
                        "volumen" => "55"
                        "paginaInicial" => "218"
                        "paginaFinal" => "223"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8733437"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "CTRI&#47;2021&#47;07&#47;035307&#46; To understand the immunogenicity of Covisheild vaccine in patients with rheumatological disease by discontinuing methotrexate temporarily after taking second dose of vaccine&#46; <a target="_blank" href="https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/07/035307">https&#58;&#47;&#47;trialsearch&#46;who&#46;int&#47;Trial2&#46;aspx&#63;TrialID&#61;CTRI&#47;2021&#47;07&#47;035307</a> &#91;Internet&#93;&#46; Available from&#58; <a target="_blank" href="https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02328327/full">https&#58;&#47;&#47;www&#46;cochranelibrary&#46;com&#47;central&#47;doi&#47;10&#46;1002&#47;central&#47;CN-02328327&#47;full</a> &#91;cited 16&#46;04&#46;23&#93;&#46;"
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase &#40;PMR MODE&#41;&#58; study protocol for a multicenter double-blind placebo controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "D&#46;E&#46; Marsman"
                            1 => "T&#46;E&#46; Bolhuis"
                            2 => "N&#46; den Broeder"
                            3 => "A&#46;A&#46; den Broeder"
                            4 => "A&#46; van der Maas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1186/s13063-022-06263-3"
                      "Revista" => array:5 [
                        "tituloSerie" => "Trials"
                        "fecha" => "2022"
                        "volumen" => "23"
                        "paginaInicial" => "318"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35428320"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1186/s13063-022-06263-3"
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;doi&#46;org&#47;10&#46;1186&#47;s13063-022-06263-3"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "FRI0216 steroid sparing effect lower incidence of disease relapse and diabetes in giant cell arteritis treated with immunosuppressors ab initio or very early&#58; a multicenter retrospective case&#8211;control study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Quartuccio"
                            1 => "M&#46; Isola"
                            2 => "D&#46; Bruno"
                            3 => "E&#46; Treppo"
                            4 => "L&#46; Gigante"
                            5 => "F&#46; Angelotti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2020"
                        "volumen" => "79"
                        "numero" => "Suppl&#46; 1"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;L&#46; G&#233;rard"
                            1 => "N&#46; Simon-Tillaux"
                            2 => "Y&#46; Yordanov"
                            3 => "P&#46; Cacoub"
                            4 => "F&#46; Tubach"
                            5 => "D&#46; Saadoun"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejim.2021.03.040"
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur J Intern Med"
                        "fecha" => "2021"
                        "volumen" => "88"
                        "paginaInicial" => "96"
                        "paginaFinal" => "103"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33879385"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673619312796"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Indirect comparison of glucocorticoid-sparing agents for remission maintenance in giant cell arteritis&#58; a network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Mainbourg"
                            1 => "A&#46; Tabary"
                            2 => "M&#46; Cucherat"
                            3 => "F&#46; Gueyffier"
                            4 => "H&#46; Lobbes"
                            5 => "M&#46; Aussedat"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.mayocp.2022.03.010"
                      "Revista" => array:7 [
                        "tituloSerie" => "Mayo Clin Proc"
                        "fecha" => "2022"
                        "volumen" => "97"
                        "paginaInicial" => "1824"
                        "paginaFinal" => "1835"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35995627"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1473309921004588"
                          "estado" => "S300"
                          "issn" => "14733099"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparing treatment options for large vessel vasculitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "F&#46; Macaluso"
                            1 => "C&#46; Marvisi"
                            2 => "P&#46; Castrignan&#242;"
                            3 => "N&#46; Pipitone"
                            4 => "C&#46; Salvarani"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/1744666X.2022.2092098"
                      "Revista" => array:7 [
                        "tituloSerie" => "Expert Rev Clin Immunol"
                        "fecha" => "2022"
                        "volumen" => "18"
                        "paginaInicial" => "793"
                        "paginaFinal" => "805"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35714219"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1473309921004539"
                          "estado" => "S300"
                          "issn" => "14733099"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatments for giant cell arteritis&#58; meta-analysis and assessment of estimates reliability using the fragility index"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Berti"
                            1 => "D&#46; Cornec"
                            2 => "J&#46;R&#46; Medina Inojosa"
                            3 => "E&#46;L&#46; Matteson"
                            4 => "M&#46;H&#46; Murad"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2017.12.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum"
                        "fecha" => "2018"
                        "volumen" => "48"
                        "paginaInicial" => "77"
                        "paginaFinal" => "82"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29496228"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Updates in the diagnosis and management of giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46; Uppal"
                            1 => "M&#46; Hadi"
                            2 => "S&#46; Chhaya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11910-019-0982-3"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Neurol Neurosci Rep"
                        "fecha" => "2019"
                        "volumen" => "19"
                        "paginaInicial" => "68"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31396718"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "G&#46;S&#46; Hoffman"
                            1 => "R&#46;Y&#46; Leavitt"
                            2 => "G&#46;S&#46; Kerr"
                            3 => "M&#46; Rottem"
                            4 => "M&#46;C&#46; Sneller"
                            5 => "A&#46;S&#46; Fauci"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "1994"
                        "volumen" => "37"
                        "paginaInicial" => "578"
                        "paginaFinal" => "582"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A multicenter&#44; randomized&#44; double-blind&#44; placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;S&#46; Hoffman"
                            1 => "M&#46;C&#46; Cid"
                            2 => "D&#46;B&#46; Hellmann"
                            3 => "L&#46; Guillevin"
                            4 => "J&#46;H&#46; Stone"
                            5 => "J&#46; Schousboe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.10262"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2002"
                        "volumen" => "46"
                        "paginaInicial" => "1309"
                        "paginaFinal" => "1318"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12115238"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adalimumab for steroid sparing in patients with giant-cell arteritis&#58; results of a multicentre randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Seror"
                            1 => "G&#46; Baron"
                            2 => "E&#46; Hachulla"
                            3 => "M&#46; Debandt"
                            4 => "C&#46; Larroche"
                            5 => "X&#46; Pu&#233;chal"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2013-203586"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2014"
                        "volumen" => "73"
                        "paginaInicial" => "2074"
                        "paginaFinal" => "2081"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23897775"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46;M&#46; Mart&#237;nez-Taboada"
                            1 => "V&#46; Rodr&#237;guez-Valverde"
                            2 => "L&#46; Carre&#241;o"
                            3 => "J&#46; L&#243;pez-Longo"
                            4 => "M&#46; Figueroa"
                            5 => "J&#46; Belzunegui"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2007.082115"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2008"
                        "volumen" => "67"
                        "paginaInicial" => "625"
                        "paginaFinal" => "630"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18086726"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis&#58; a randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;S&#46; Hoffman"
                            1 => "M&#46;C&#46; Cid"
                            2 => "K&#46;E&#46; Rendt-Zagar"
                            3 => "P&#46;A&#46; Merkel"
                            4 => "C&#46;M&#46; Weyand"
                            5 => "J&#46;H&#46; Stone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-146-9-200705010-00004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2007"
                        "volumen" => "146"
                        "paginaInicial" => "621"
                        "paginaFinal" => "630"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17470830"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Azathioprine in giant cell arteritis&#47;polymyalgia rheumatica&#58; a double-blind study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; De Silva"
                            1 => "B&#46;L&#46; Hazleman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.45.2.136"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "1986"
                        "volumen" => "45"
                        "paginaInicial" => "136"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3511861"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis&#58; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "T&#46; Adizie"
                            1 => "D&#46; Christidis"
                            2 => "C&#46; Dharmapaliah"
                            3 => "F&#46; Borg"
                            4 => "B&#46; Dasgupta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1742-1241.2012.02981.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Clin Pract"
                        "fecha" => "2012"
                        "volumen" => "66"
                        "paginaInicial" => "906"
                        "paginaFinal" => "909"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22897467"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica&#58; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;P&#46; Diamantopoulos"
                            1 => "H&#46; Hetland"
                            2 => "G&#46; Myklebust"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Biomed Res Int"
                        "fecha" => "2013"
                        "volumen" => "2013"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized double-blind trial of abatacept &#40;CTLA-4Ig&#41; for the treatment of giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;A&#46; Langford"
                            1 => "D&#46; Cuthbertson"
                            2 => "S&#46;R&#46; Ytterberg"
                            3 => "N&#46; Khalidi"
                            4 => "P&#46;A&#46; Monach"
                            5 => "S&#46; Carette"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.40044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheumatol"
                        "fecha" => "2017"
                        "volumen" => "69"
                        "paginaInicial" => "837"
                        "paginaFinal" => "845"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28133925"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ustekinumab for the treatment of refractory giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Conway"
                            1 => "L&#46; O&#8217;Neill"
                            2 => "E&#46; O&#8217;Flynn"
                            3 => "P&#46; Gallagher"
                            4 => "G&#46;M&#46; McCarthy"
                            5 => "C&#46;C&#46; Murphy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2016-209351"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2016"
                        "volumen" => "75"
                        "paginaInicial" => "1578"
                        "paginaFinal" => "1579"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27143653"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "C&#46;M&#46; Weyand"
                            1 => "K&#46;C&#46; Hicok"
                            2 => "G&#46;G&#46; Hunder"
                            3 => "J&#46;J&#46; Goronzy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-121-7-199410010-00003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "1994"
                        "volumen" => "121"
                        "paginaInicial" => "484"
                        "paginaFinal" => "491"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8067646"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of giant cell arteritis&#58; interleukin-6 as a biologic marker of disease activity"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46;M&#46; Weyand"
                            1 => "J&#46;W&#46; Fulbright"
                            2 => "G&#46;G&#46; Hunder"
                            3 => "J&#46;M&#46; Evans"
                            4 => "J&#46;J&#46; Goronzy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2000"
                        "volumen" => "43"
                        "paginaInicial" => "1041"
                        "paginaFinal" => "1048"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10817557"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IFN-&#947; and IL-17&#58; the two faces of T-cell pathology in giant cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46;M&#46; Weyand"
                            1 => "B&#46;R&#46; Younge"
                            2 => "J&#46;J&#46; Goronzy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0b013e32833ee946"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol"
                        "fecha" => "2011"
                        "volumen" => "23"
                        "paginaInicial" => "43"
                        "paginaFinal" => "49"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20827207"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Trial of tocilizumab in giant-cell arteritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;H&#46; Stone"
                            1 => "K&#46; Tuckwell"
                            2 => "S&#46; Dimonaco"
                            3 => "M&#46; Klearman"
                            4 => "M&#46; Aringer"
                            5 => "D&#46; Blockmans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1613849"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "377"
                        "paginaInicial" => "317"
                        "paginaFinal" => "328"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28745999"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tocilizumab for induction and maintenance of remission in giant cell arteritis&#58; a phase 2&#44; randomised&#44; double-blind&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;M&#46; Villiger"
                            1 => "S&#46; Adler"
                            2 => "S&#46; Kuchen"
                            3 => "F&#46; Wermelinger"
                            4 => "D&#46; Dan"
                            5 => "V&#46; Fiege"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(16)00560-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2016"
                        "volumen" => "387"
                        "paginaInicial" => "1921"
                        "paginaFinal" => "1927"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26952547"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000108/v1_202402220812/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "67860"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Case reports"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735743/0000002000000002/v1_202402220812/S2173574324000108/v1_202402220812/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000108?idApp=UINPBA00004M"
]

Article information

ISSN: 21735743
Original language: English

DOI:10.1016/j.reumae.2024.01.003

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	9	18	27
2024 October	39	27	66
2024 September	45	21	66
2024 August	51	46	97
2024 April	2	0	2
2024 March	2	2	4

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter